• Opaleye Management, a 10% owner of Grace Therapeutics, purchased 87,801 common shares, bringing indirect holdings to 3,036,411 shares.
• Purchases comprised 21,390 shares at $1.9258 per share and 66,411 shares at $1.7679 per share.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Grace Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-048591), on October 26, 2026, and is solely responsible for the information contained therein.